Ivermectin is best known as a Nobel Prize-winning anti-parasitic medication. Less well known is a research thread, dating back to 1995, exploring whether the same drug might have a role to play against cancer. The evidence so far is preclinical and early — but it comes from credentialed researchers at recognized institutions, and it raises questions worth understanding, especially for anyone trying to make sense of integrative options alongside conventional oncology care.
Where the Idea Came From
The first reports of ivermectin's anti-cancer activity came from French researchers who found it could reverse multidrug resistance in tumors. Since then, laboratory research has pointed to several possible mechanisms: the drug appears to target cancer stem cells (a driver of both tumor growth and relapse), induce mitochondrial stress in cancer cells, inhibit the cell cycle that produces new cancer cells, and block the formation of new blood vessels that tumors rely on for fuel.
According to Dr. Alfonso Dueñas-González, an oncologist and senior researcher at the National Autonomous University of Mexico, at least nine distinct cancer-relevant targets have been identified for the drug. His own laboratory work has found that at least 26 different cancer cell lines — including breast, prostate, colon, ovarian, lung, and pancreatic cancers — respond to ivermectin in the lab.
An Immune System Angle, Not Just a Direct Attack
What distinguishes this research from many conventional cancer therapies is the proposed mechanism. Chemotherapy and radiation typically work by damaging cancer cell DNA directly — while also damaging and suppressing the immune system in the process. Dr. Peter Lee, chair of immuno-oncology at City of Hope, has focused his research on a different angle: what he calls immunogenic cell death, where ivermectin appears to kill cancer cells in a way that actively recruits the immune system into the fight.
In his lab's mouse studies, ivermectin turned immunologically "cold" tumors "hot" — meaning immune cells began appearing in tumors that previously had none, a state generally associated with better outcomes and lower recurrence risk. Notably, ivermectin alone wasn't enough to stop tumor growth in these studies. It was the combination with an immunotherapy drug (a PD-1 checkpoint inhibitor) that cleared tumors and prevented new ones from forming after the mice were re-exposed to cancer cells. As Dr. Lee put it, "ivermectin has a lot of promise for cancer, but probably not as a stand-alone treatment."
What Human Evidence Exists — and Its Limits
Here is where real caution is warranted: clinical studies in humans remain scarce, small, and not the kind of rigorous randomized trials that establish whether a treatment reliably works. A small study followed three children with acute myeloid leukemia given ivermectin alongside chemotherapy after conventional treatment failed; two saw temporary symptom improvement, one did not respond, and all three ultimately succumbed to the disease. A separate small Japanese study described symptom improvement in two of three adult patients with different cancers after ivermectin was added to their treatment combinations.
Patient case reports — including a colon cancer patient whose tumor markers dropped sharply after adding ivermectin to his chemotherapy and radiation, and a breast cancer surgeon's account of three patients with dramatic responses — have drawn attention to the drug. These stories are genuinely striking, and they're part of why researchers are pursuing the question further. But individual cases, however compelling, can't establish whether a treatment works reliably across a population, or separate its effect from that of the other therapies patients were receiving at the same time. Dr. Lee's team has now opened a formal clinical trial combining ivermectin with immunotherapy for women with metastatic breast cancer — the kind of controlled study that can actually answer the question.
It's also worth noting that not every research lead has panned out. A separate line of investigation into ivermectin's ability to block a stress protein involved in treatment recovery was abandoned by researchers at the University of British Columbia after the effective dose in animal studies raised concerns about neurotoxicity — a reminder that promising lab mechanisms don't automatically translate into a safe or workable human treatment.
Where This Leaves Patients and Practitioners
Some physicians are already incorporating ivermectin into integrative cancer protocols, typically alongside conventional treatment rather than in place of it, and typically as part of a broader combination of therapies — which itself makes it hard to isolate ivermectin's individual contribution from the rest of the protocol. That ambiguity is honestly acknowledged by several of the physicians using it this way.
The responsible takeaway here isn't "ivermectin cures cancer," nor is it dismissal of a research direction with real scientific grounding behind it. It's that this is an active, evolving area of oncology research — promising enough to warrant properly designed clinical trials, and not yet mature enough to guide treatment decisions on its own. Anyone considering ivermectin, or any complementary therapy, during cancer treatment should bring it directly to their oncology team, both to weigh the evidence honestly and to check for interactions with existing treatment.
"I know that I know nothing." — Socrates